Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Натулан при лечении лимфомы Ходжкина: от МОРР до ВЕАСОРР
Натулан при лечении лимфомы Ходжкина: от МОРР до ВЕАСОРР
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Coltman CA. Chemotherapy of advansed Hodgkin’s lymphoma. Semin Oncol 1980; 7: 155–73.
2. Diehl V, Behringer K. Could BEACOPP Be the New Standard for the Treatment of Advanced Hodgkin’s Lymphoma? Cancer Investigation 2006; 24: 261–5.
3. Cancer. Principles & Practice of Oncology. 3rd ed. Eds. V.T.DeVita, S.Hellman, S.A.Rosenberg. Philadelphia: Lippincott-Raven Publishers, 1989; 1696–739.
4. De Vita VT, Serpick AA. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Proc Am Assoc Cancer Res 1967; 8: 13.
5. De Vita VT, Simon RM, Hubbard SM et al. Currability of advanced Hodgkin’s disease with chemotherapy. Long-term follow up of MOPP treated patients at NCI. Ann Intern Med 1980; 92: 587–95.
6. Zeller P, Gutmann H, Hegedus B et al. Methylhydrazine derivates. a new class of cytotoxic agents. Experimenta 1963; 19: 129.
7. Newell D, Gescher A, Harland S et al. N-methyl antitumor agents: a distinct class of anticancer drags? Cancer Chemother Pharmacol 1987; 19: 91–102.
8. Erikson JM, Tweedie DJ, Ducore JM et al. Cytotoxicity and DNA damage caused by the azoxy metabolites of procarbazine in L1210 tumor cells. Cancer Res 1989; 49: 127–33.
9. Armand J-P, Ribrag V, Harrouseau J-L et al. Reppraisal of the Use of Procarbasine in the Treatment of Lymphomas and Brain Tumors. Ther Clin Risk Manag 2007; 3 (2): 213–24.
10. Brunner KW, Yong CW. A methylhydrazine derivative in Hodgkin’s disease and other malignant neoplasms. Therapeutic and toxic effects studied in 51patients. Ann Intern Med 1965; 63: 69–86.
11. Preiss R, Baumann F, Regenthal R et al. Plasma kinetics of procarbazine and azo- procarbazine in humans. Anti-Cancer Drugs 2006; 17: 75–80.
12. Bonadonna G. Histirical review of Hodgkin’s disease. Brit J Haematol 2000; 110: 504–11.
13. Ng AK, Bernardo MV, Weller W et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100: 1989–6.
14. Hodgkin’s disease. Ed. P.V.Mauch, J.O.Armitage, V.Diehl et al. Philadelphia, 2007.
15. Bramswig JH, Hornig-Franz I, Riepenhausen M et al. The challenge of pediatric Hodgkin’s disease – where is the balance between cure and Long-term toxicity? A report of the West German Multicenter Studies DAL-HD-78, DAL-HD-82, DAL-HD-85. Leuk Lymphoma 1990; 2: 183.
16. Schelong G, Bramswig JH, Hornig-Franz I et al. Treatment of children with Hodgkin’s disease. Results of the German Pediatric Oncology Group. Ann Oncol 1992; 3: S73.
17. Bonnadonna G, Zucaly R, Monfardini S et al. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252–9.
18. Federico M, Luminary S, Dell’Olio M et al., ABVD vs. COPPTBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin lymphoma (HL)/Preliminary results of HD2000 GISL trail. Haematologica 2007; s5: 34 abstr C026.
19. Diehl V, Franklin J, Hasenclever D et al. BEACOPP: A new regimen for advanced stage Hodgkin’s disease. Ann Oncol 1998; 9 (Suppl. 5): 67–71.
20. Franklin J, Diehl V. Сurrent clinical trails for the treatment of advanced stage Hodgkin’s disease: BEACOPP. Ann Oncol 2002; 13 (Suppl. 1): 98–101.
21. De Bruin ML, Huisbrink JM, Hauptmann M et al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 2008; 111: 101–8.
22. Sieniawski М, Reineke Т, Nogova L et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008; 111: 71–6.
23. Sieber M, Bredenfeld H, Josting A et al. 14-Day Variant of the Bleomycin, Etoposide, Doxorubicin,Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin’s Lymphoma: Results of aPilot Study of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2003; 21: 1734–9.
24. Hampton T. Phase 3 Trials Suggest Ways to Improve Current Hematologic Cancer Therapies; JAMA 2008; 299 (5): 510–2 (doi: 10.1001/jama.299.5.510).
25. ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo studio dei Linfomi Trial. J Clin Oncol 2009; 5.
2. Diehl V, Behringer K. Could BEACOPP Be the New Standard for the Treatment of Advanced Hodgkin’s Lymphoma? Cancer Investigation 2006; 24: 261–5.
3. Cancer. Principles & Practice of Oncology. 3rd ed. Eds. V.T.DeVita, S.Hellman, S.A.Rosenberg. Philadelphia: Lippincott-Raven Publishers, 1989; 1696–739.
4. De Vita VT, Serpick AA. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Proc Am Assoc Cancer Res 1967; 8: 13.
5. De Vita VT, Simon RM, Hubbard SM et al. Currability of advanced Hodgkin’s disease with chemotherapy. Long-term follow up of MOPP treated patients at NCI. Ann Intern Med 1980; 92: 587–95.
6. Zeller P, Gutmann H, Hegedus B et al. Methylhydrazine derivates. a new class of cytotoxic agents. Experimenta 1963; 19: 129.
7. Newell D, Gescher A, Harland S et al. N-methyl antitumor agents: a distinct class of anticancer drags? Cancer Chemother Pharmacol 1987; 19: 91–102.
8. Erikson JM, Tweedie DJ, Ducore JM et al. Cytotoxicity and DNA damage caused by the azoxy metabolites of procarbazine in L1210 tumor cells. Cancer Res 1989; 49: 127–33.
9. Armand J-P, Ribrag V, Harrouseau J-L et al. Reppraisal of the Use of Procarbasine in the Treatment of Lymphomas and Brain Tumors. Ther Clin Risk Manag 2007; 3 (2): 213–24.
10. Brunner KW, Yong CW. A methylhydrazine derivative in Hodgkin’s disease and other malignant neoplasms. Therapeutic and toxic effects studied in 51patients. Ann Intern Med 1965; 63: 69–86.
11. Preiss R, Baumann F, Regenthal R et al. Plasma kinetics of procarbazine and azo- procarbazine in humans. Anti-Cancer Drugs 2006; 17: 75–80.
12. Bonadonna G. Histirical review of Hodgkin’s disease. Brit J Haematol 2000; 110: 504–11.
13. Ng AK, Bernardo MV, Weller W et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100: 1989–6.
14. Hodgkin’s disease. Ed. P.V.Mauch, J.O.Armitage, V.Diehl et al. Philadelphia, 2007.
15. Bramswig JH, Hornig-Franz I, Riepenhausen M et al. The challenge of pediatric Hodgkin’s disease – where is the balance between cure and Long-term toxicity? A report of the West German Multicenter Studies DAL-HD-78, DAL-HD-82, DAL-HD-85. Leuk Lymphoma 1990; 2: 183.
16. Schelong G, Bramswig JH, Hornig-Franz I et al. Treatment of children with Hodgkin’s disease. Results of the German Pediatric Oncology Group. Ann Oncol 1992; 3: S73.
17. Bonnadonna G, Zucaly R, Monfardini S et al. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252–9.
18. Federico M, Luminary S, Dell’Olio M et al., ABVD vs. COPPTBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin lymphoma (HL)/Preliminary results of HD2000 GISL trail. Haematologica 2007; s5: 34 abstr C026.
19. Diehl V, Franklin J, Hasenclever D et al. BEACOPP: A new regimen for advanced stage Hodgkin’s disease. Ann Oncol 1998; 9 (Suppl. 5): 67–71.
20. Franklin J, Diehl V. Сurrent clinical trails for the treatment of advanced stage Hodgkin’s disease: BEACOPP. Ann Oncol 2002; 13 (Suppl. 1): 98–101.
21. De Bruin ML, Huisbrink JM, Hauptmann M et al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 2008; 111: 101–8.
22. Sieniawski М, Reineke Т, Nogova L et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008; 111: 71–6.
23. Sieber M, Bredenfeld H, Josting A et al. 14-Day Variant of the Bleomycin, Etoposide, Doxorubicin,Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin’s Lymphoma: Results of aPilot Study of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2003; 21: 1734–9.
24. Hampton T. Phase 3 Trials Suggest Ways to Improve Current Hematologic Cancer Therapies; JAMA 2008; 299 (5): 510–2 (doi: 10.1001/jama.299.5.510).
25. ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo studio dei Linfomi Trial. J Clin Oncol 2009; 5.
Авторы
Е.А.Демина
ГУ Онкологический научный центр им. Н.Н.Блохина РАМН, Москва
ГУ Онкологический научный центр им. Н.Н.Блохина РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.